Results 241 to 250 of about 11,332,305 (264)
Some of the next articles are maybe not open access.

Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities

Neurology
In the last 2 years, there have been 3 successful trials of antiamyloid antibodies in Alzheimer disease (AD): aducanemab, now controversially US Food and Drug Administration-approved under the accelerated approval pathway1; lecanemab, now FDA-approved2; and donanemab, now going through the approval process.3 All 3 share a common broad mechanism, that ...
John, Hardy, Jonathan M, Schott
openaire   +2 more sources

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

Journal of Alzheimer's Disease, 2018
Background: Amyloid-related imaging abnormalities with effusion or edema (ARIA-E) reported in patients with mild-to-moderate Alzheimer’s disease in bapineuzumab phase III studies. Objectives: Assess symptoms, clinical severity, and ARIA-E outcomes, and to evaluate effects on cognition and function.
H Robert, Brashear   +5 more
openaire   +2 more sources

Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities

Neurology
To report a case of fatal super-refractory status epilepticus associated with amyloid-related imaging abnormalities (ARIA).We describe the history, neuroimaging, EEG, and brain pathology findings of a 75-year-old patient with mild cognitive impairment due to Alzheimer disease (homozygous ε4 apolipoprotein status) and a remote history of 3 asymptomatic ...
Joel Neves Briard   +3 more
openaire   +2 more sources

Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab

JAMA Neurology, 2022
Jacob N, Hall   +6 more
openaire   +2 more sources

Molecular Imaging in Oncology: Current Impact and Future Directions

Ca-A Cancer Journal for Clinicians, 2022
Martin G. Pomper, Steven P Rowe
exaly  

Amyloid-Related Imaging Abnormalities (ARIA): essential insights for diagnosis and management

Learning objectives: 1. Explain the pathophysiology of ARIA in the context of Alzheimer’s disease and provide a brief overview of monoclonal antibodies used in its treatment. 2.
openaire   +1 more source

Home - About - Disclaimer - Privacy